Monika Durak
Jagiellonian University Medical College
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Monika Durak.
International Journal of Cardiology | 2011
Jarosław Zalewski; Krzysztof Nycz; Tadeusz Przewłocki; Monika Durak; Michal Cul; Wojciech Zajdel; Krzysztof Zmudka
BACKGROUND TIMI myocardial perfusion grade (TMPG) reflects the integrity of microvasculature in ST-elevation myocardial infarction (STEMI). We sought to investigate whether TMPG evolution during primary angioplasty (pPCI) in spontaneously reperfused STEMI patients might predict long-term outcomes. METHODS 392 patients with TIMI-3 flow before pPCI were analyzed. According to pre- and post-pPCI TMPG four reperfusion patterns were created: A. TMPG deterioration from grade 2/3 to 0/1 after pPCI (n = 55, 14.0%), B. TMPG-0/1 before and after pPCI (n = 111, 28.3%), C. TMPG improvement from grade 0/1 to 2/3 (n = 52, 13.3%), D. TMPG-2/3 before and after pPCI (n = 174, 44.4%). 30-day and 1-year mortality and heart failure requiring hospitalization (HF-hosp) were recorded. Left ventricular ejection fraction (LVEF) was measured at first day (1D) and after 6 months (6M). RESULTS 1D-LVEF was similar in A-D groups. After 6M, LVEF improved in pattern D (7.5 ± 5.4%, p<0.01) and C (3.7 ± 3.4%, p < 0.05), deteriorated in pattern A (5.2 ± 3.9%, p<0.01) and did not change in pattern B. 6M-LVEF increased (p < 0.001) and frequency of 1-year HF-hosp decreased (p < 0.001) in stepwise fashion among A-D patterns. A 30-day mortality rate for A-D patterns was 9.1%, 2.7%, 1.9% and 0%, respectively (p < 0.001). 1-year mortality was 16.3%, 7.2%, 5.8% and 0.6%, respectively (p < 0.001). By multivariate analysis (c-index = 0.79), TMPG evolution was independent predictor of 1-year mortality (HR = 2.5, 95%CI 1.3-4.0, p = 0.006). CONCLUSIONS Maintaining TMPG-2/3 or improving TMPG-0/1 through pPCI in STEMI implies LV function recovery and good long-term survival. In contrast, substantial deterioration of TMPG is associated with lack of LV function recovery, and the highest mortality rate.
European Heart Journal | 2018
Stefan Janssens; Jan Bogaert; Jaroslaw Zalewski; A. Tóth; Tom Adriaenssens; Ann Belmans; Johan Bennett; Piet Claus; Walter Desmet; Christophe Dubois; Kaatje Goetschalckx; Peter Sinnaeve; Katleen Vandenberghe; Pieter Vermeersch; Árpád Lux; Zsolt Szelid; Monika Durak; Piotr Lech; Krzysztof Zmudka; Peter Pokreisz; Pascal Vranckx; Béla Merkely; Kenneth D. Bloch; Frans Van de Werf
Aims Inhalation of nitric oxide (iNO) during myocardial ischaemia and after reperfusion confers cardioprotection in preclinical studies via enhanced cyclic guanosine monophosphate (cGMP) signalling. We tested whether iNO reduces reperfusion injury in patients with ST-elevation myocardial infarction (STEMI; NCT01398384). Methods and results We randomized in a double-blind, placebo-controlled study 250 STEMI patients to inhale oxygen with (iNO) or without (CON) 80 parts-per-million NO for 4 h following percutaneous revascularization. Primary efficacy endpoint was infarct size as a fraction of left ventricular (LV) size (IS/LVmass), assessed by delayed enhancement contrast magnetic resonance imaging (MRI). Pre-specified subgroup analysis included thrombolysis-in-myocardial-infarction flow in the infarct-related artery, troponin T levels on admission, duration of symptoms, location of culprit lesion, and intra-arterial nitroglycerine (NTG) use. Secondary efficacy endpoints included IS relative to risk area (IS/AAR), myocardial salvage index, LV functional recovery, and clinical events at 4 and 12 months. In the overall population, IS/LVmass at 48-72 h was 18.0 ± 13.4% in iNO (n = 109) and 19.4 ± 15.4% in CON [n = 116, effect size -1.524%, 95% confidence interval (95% CI) -5.28, 2.24; P = 0.427]. Subgroup analysis indicated consistency across clinical confounders of IS but significant treatment interaction with NTG (P = 0.0093) resulting in smaller IS/LVmass after iNO in NTG-naïve patients (n = 140, P < 0.05). The secondary endpoint IS/AAR was 53 ± 26% with iNO vs. 60 ± 26% in CON (effect size -6.8%, 95% CI -14.8, 1.3, P = 0.09) corresponding to a myocardial salvage index of 47 ± 26% vs. 40 ± 26%, respectively, P = 0.09. Cine-MRI showed similar LV volumes at 48-72 h, with a tendency towards smaller increases in end-systolic and end-diastolic volumes at 4 months in iNO (P = 0.048 and P = 0.06, respectively, n = 197). Inhalation of nitric oxide was safe and significantly increased cGMP plasma levels during 4 h reperfusion. The Kaplan-Meier analysis for the composite of death, recurrent ischaemia, stroke, or rehospitalizations showed a tendency toward lower event rates with iNO at 4 months and 1 year (log-rank test P = 0.10 and P = 0.06, respectively). Conclusions Inhalation of NO at 80 ppm for 4 h in STEMI was safe but did not reduce infarct size relative to absolute LVmass at 48-72h. The observed functional recovery and clinical event rates at follow-up and possible interaction with nitroglycerine warrant further studies of iNO in STEMI.
Journal of Clinical and Experimental Cardiology | 2016
Wojciech Zajdel; Marek Andres; Monika Durak; Marek Tomala; Piotr Musialek; Krzysztof Zmudka
Background: A 63-year-old female with a chronic total occlusion (CTO) of the left main coronary artery (LMCA) after multiple percutaneous coronary interventions (PCI) and triple coronary bypass surgery (CABG). Investigation: physical examination, EKG, TTE, coronary angiography, appropriate lesion preparation before stenting of the LMCA. Diagnosis: Multivessel coronary artery disease presenting as CCS third class with ostial LMCA chronic total occlusion and unsuccessful consecutive revascularization. Management: Recanalization of the LMCA CTO, preparation of the lesion by rotational atherectomy, reverses T-stenting of LMCA.
Jacc-cardiovascular Imaging | 2017
Rolf Symons; Gianluca Pontone; Juerg Schwitter; Marco Francone; Juan F. Iglesias; Andrea Barison; Jaroslaw Zalewski; Laura De Luca; Sophie Degrauwe; Piet Claus; Marco Guglielmo; Jadwiga Nessler; Iacopo Carbone; Giovanni Ferro; Monika Durak; Paolo Magistrelli; Alfonso Lo Presti; Giovanni Donato Aquaro; Eric Eeckhout; Christian Roguelov; Daniele Andreini; Pierre Vogt; Andrea Igoren Guaricci; Saima Mushtaq; Valentina Lorenzoni; Olivier Muller; Walter Desmet; Luciano Agati; Stefan Janssens; Jan Bogaert
Kardiologia Polska | 2012
Jarosław Zalewski; Monika Durak; Piotr Lech; Grzegorz Gajos; Anetta Undas; Jadwiga Nessler; Agnieszka Rosławiecka; Krzysztof Żmudka
Kardiologia Polska | 2004
Krzysztof Zmudka; Jarosław Zalewski; T. Przewlocki; Wojciech Zajdel; Czunko P; Monika Durak; Zorkun C; Piotr Podolec; Wiesława Tracz
Advances in Interventional Cardiology | 2010
Jarosław Zalewski; Krzysztof Nycz; Tadeusz Przewłocki; Monika Durak; Marek Andres; Piotr Lech; Piotr Pieniążek; Krzysztof Żmudka
Advances in Interventional Cardiology | 2018
Jakub Podolec; Piotr Szolc; Monika Durak; Wojciech Zajdel; Łukasz Niewiara; Krzysztof Żmudka
European Heart Journal | 2013
Jarosław Zalewski; Krzysztof Zmudka; Piotr Lech; Monika Durak; Jadwiga Nessler
Circulation | 2012
Jarosław Zalewski; Anetta Undas; Piotr Lech; Monika Durak; Jadwiga Nessler; Krzysztof Zmudka